Prognostic Value of Lymphocyte G Protein-Coupled Receptor Kinase-2 Protein Levels in Patients with Heart Failure

Circulation Research

Volumn 118, Issue 7, 2016, Pages 1116-1124

  Rengo, Giuseppe ^a,b   Pagano, Gennaro ^a,b   Filardi, Pasquale Perrone ^b   Femminella, Grazia Daniela ^a,b   Parisi, Valentina ^b   Cannavo, Alessandro ^b   Liccardo, Daniela ^b,d   Komici, Klara ^b   Gambino, Giuseppina ^b   D'Amico, Maria Loreta ^b   De Lucia, Claudio ^b   Paolillo, Stefania ^c   Trimarco, Bruno ^b   Vitale, Dino Franco ^d   Ferrara, Nicola ^a,b   Koch, Walter J ^d   Leosco, Dario ^b  

^a IRCCS   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c IRCCS SDN   (Italy)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

beta adrenergic receptors; G protein coupled receptor kinase 2; heart failure; natriuretic peptide, brain; prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; G PROTEIN COUPLED RECEPTOR KINASE 2; NORADRENALIN; SODIUM; ADRBK1 PROTEIN, HUMAN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADRENERGIC SYSTEM; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL OUTCOME; COMORBIDITY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; HYPERTENSION; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; NEW YORK HEART ASSOCIATION CLASS; NORADRENALIN BLOOD LEVEL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; BIOLOGICAL MODEL; BLOOD; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; ENZYMOLOGY; ETIOLOGY; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; LYMPHOCYTE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY; ALL CAUSE MORTALITY; CHRONIC KIDNEY DISEASE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; BIOMARKERS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; G-PROTEIN-COUPLED RECEPTOR KINASE 2; HEART FAILURE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; MODELS, CARDIOVASCULAR; MORTALITY; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; STROKE VOLUME; SYMPATHETIC NERVOUS SYSTEM; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84994571224     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.308207     Document Type: Article

References (48)

1. McMurray JJ, Adamopoulos S, Anker SD, ESC Committee for Practice Guidelines ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012 33 1787 1847. doi: 10.1093/eurheartj/ehs104
2. Rengo F, Leosco D, Iacovoni A, Rengo G, Golino L, Borgia F, De Lisa G, Beneduce F, Senni M, [Epidemiology and risk factors for heart failure in the elderly]. Ital Heart J 2004 5 Suppl 10 9S 16S
3. Lymperopoulos A, Rengo G, Koch WJ, Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res 2013 113 739 753. doi: 10.1161/CIRCRESAHA.113.300308
4. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J, The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009 54 1747 1762. doi: 10.1016/j.jacc.2009.05.015
5. Lymperopoulos A, Rengo G, Koch WJ, Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. Trends Mol Med 2007 13 503 511. doi: 10.1016/j.molmed.2007.10.005
6. Foody JM, Farrell MH, Krumholz HM, beta-Blocker therapy in heart failure: scientific review. JAMA 2002 287 883 889
7. Bristow MR, β-Adrenergic receptor blockade in chronic heart failure. Circulation 2000 101 558 569
8. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW, Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009 150 784 794
9. Simões MV, Barthel P, Matsunari I, Nekolla SG, Schömig A, Schwaiger M, Schmidt G, Bengel FM, Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction. Eur Heart J 2004 25 551 557. doi: 10.1016/j.ehj.2004.02.016
10. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, Agostini D, Weiland F, Chandna H, Narula J, ADMIRE-HF Investigators Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010 55 2212 2221. doi: 10.1016/j.jacc.2010.01.014
11. Floras JS, Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol 2009 54 375 385. doi: 10.1016/j.jacc.2009.03.061
12. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, Barlera S, Maggioni AP, Tognoni G, Cohn JN, Val-HeFT Investigators The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004 25 292 299. doi: 10.1016/j.ehj.2003.10.030
13. Tsutamoto T, Nishiyama K, Sakai H, Tanaka T, Fujii M, Yamamoto T, Yamaji M, Horie M, Transcardiac increase in norepinephrine and prognosis in patients with chronic heart failure. Eur J Heart Fail 2008 10 1208 1214. doi: 10.1016/j.ejheart.2008.09.011
14. Fauchier L, Babuty D, Cosnay P, Fauchier JP, Prognostic value of heart rate variability for sudden death and major arrhythmic events in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1999 33 1203 1207
15. La Rovere MT, Pinna GD, Maestri R, Mortara A, Capomolla S, Febo O, Ferrari R, Franchini M, Gnemmi M, Opasich C, Riccardi PG, Traversi E, Cobelli F, Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation 2003 107 565 570
16. Imamura Y, Fukuyama T, Prognostic value of myocardial MIBG scintigraphy findings in patients with cardiomyopathy-importance of background correction for quantification of MIBG activity. Ann Nucl Med 2002 16 387 393
17. 123I meta-iodobenzylguanidine (123I MIBG) scintigraphic study. Diabetes Care 2013 36 2395 2401. doi: 10.2337/dc12-2147
18. Perrone-Filardi P, Paolillo S, Dellegrottaglie S, Gargiulo P, Savarese G, Marciano C, Casaretti L, Cecere M, Musella F, Pirozzi E, Parente A, Cuocolo A, Assessment of cardiac sympathetic activity by MIBG imaging in patients with heart failure: a clinical appraisal. Heart 2011 97 1828 1833. doi: 10.1136/heartjnl-2011-300343
19. McMurray JJ, Adamopoulos S, Anker SD, Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology; ESC Committee for Practice Guidelines ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012 14 803 869. doi: 10.1093/eurjhf/hfs105
20. Iaccarino G, Tomhave ED, Lefkowitz RJ, Koch WJ, Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. Circulation 1998 98 1783 1789
21. Rengo G, Lymperopoulos A, Leosco D, Koch WJ, GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol 2011 57 356 365
22. Rengo G, Lymperopoulos A, Koch WJ, Future g protein-coupled receptor targets for treatment of heart failure. Curr Treat Options Cardiovasc Med 2009 11 328 338
23. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB, Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982 307 205 211. doi: 10.1056/NEJM198207223070401
24. Feldman DS, Carnes CA, Abraham WT, Bristow MR, Mechanisms of disease: beta-adrenergic receptors-alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med 2005 2 475 483. doi: 10.1038/ncpcardio0309
25. Tilley DG, Rockman HA, Role of beta-adrenergic receptor signaling and desensitization in heart failure: new concepts and prospects for treatment. Expert Rev Cardiovasc Ther 2006 4 417 432. doi: 10.1586/14779072.4.3.417
26. Rengo G, Lymperopoulos A, Zincarelli C, Donniacuo M, Soltys S, Rabinowitz JE, Koch WJ, Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 2009 119 89 98. doi: 10.1161/CIRCULATIONAHA.108.803999
27. Rengo G, Lymperopoulos A, Zincarelli C, Femminella G, Liccardo D, Pagano G, de Lucia C, Cannavo A, Gargiulo P, Ferrara N, Perrone Filardi P, Koch W, Leosco D, Blockade of β-adrenoceptors restores the GRK2-mediated adrenal α(2) -adrenoceptor-catecholamine production axis in heart failure. Br J Pharmacol 2012 166 2430 2440. doi: 10.1111/j.1476-5381.2012.01972.x
28. Rengo G, Zincarelli C, Femminella GD, Liccardo D, Pagano G, de Lucia C, Altobelli GG, Cimini V, Ruggiero D, Perrone-Filardi P, Gao E, Ferrara N, Lymperopoulos A, Koch WJ, Leosco D, Myocardial β(2) -adrenoceptor gene delivery promotes coordinated cardiac adaptive remodelling and angiogenesis in heart failure. Br J Pharmacol 2012 166 2348 2361. doi: 10.1111/j.1476-5381.2012.01954.x
29. Salazar NC, Vallejos X, Siryk A, Rengo G, Cannavo A, Liccardo D, De Lucia C, Gao E, Leosco D, Koch WJ, Lymperopoulos A, GRK2 blockade with βARKct is essential for cardiac β2-adrenergic receptor signaling towards increased contractility. Cell Commun Signal 2013 11 64. doi: 10.1186/1478-811X-11-64
30. Raake PW, Vinge LE, Gao E, Boucher M, Rengo G, Chen X, DeGeorge BR Jr, Matkovich S, Houser SR, Most P, Eckhart AD, Dorn GW 2nd, Koch WJ, G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res 2008 103 413 422. doi: 10.1161/CIRCRESAHA.107.168336
31. Raake PW, Schlegel P, Ksienzyk J, Reinkober J, Barthelmes J, Schinkel S, Pleger S, Mier W, Haberkorn U, Koch WJ, Katus HA, Most P, Müller OJ, AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J 2013 34 1437 1447. doi: 10.1093/eurheartj/ehr447
32. Iaccarino G, Barbato E, Cipolletta E, De Amicis V, Margulies KB, Leosco D, Trimarco B, Koch WJ, Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur Heart J 2005 26 1752 1758. doi: 10.1093/eurheartj/ehi429
33. Rengo G, Perrone-Filardi P, Femminella GD, Liccardo D, Zincarelli C, de Lucia C, Pagano G, Marsico F, Lymperopoulos A, Leosco D, Targeting the β-adrenergic receptor system through G-protein-coupled receptor kinase 2: a new paradigm for therapy and prognostic evaluation in heart failure: from bench to bedside. Circ Heart Fail 2012 5 385 391. doi: 10.1161/CIRCHEARTFAILURE.112.966895
34. Bonita RE, Raake PW, Otis NJ, Chuprun JK, Spivack T, Dasgupta A, Whellan DJ, Mather PJ, Koch WJ, Dynamic changes in lymphocyte GRK2 levels in cardiac transplant patients: a biomarker for left ventricular function. Clin Transl Sci 2010 3 14 18. doi: 10.1111/j.1752-8062.2010.00176.x
35. Hata JA, Williams ML, Schroder JN, Lima B, Keys JR, Blaxall BC, Petrofski JA, Jakoi A, Milano CA, Koch WJ, Lymphocyte levels of GRK2 (betaARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved beta-adrenergic signaling after mechanical unloading. J Card Fail 2006 12 360 368. doi: 10.1016/j.cardfail.2006.02.011
36. Rengo G, Galasso G, Femminella GD, Reduction of lymphocyte G protein-coupled receptor kinase-2 (GRK2) after exercise training predicts survival in patients with heart failure. Eur J Prev Cardiol 2014 21 4 11. doi: 10.1177/2047487313491656
37. Karl J, Borgya A, Gallusser A, Huber E, Krueger K, Rollinger W, Schenk J, Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl 1999 230 177 181
38. Royston P, Ambler G, Sauerbrei W, The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999 28 964 974
39. Royston P, Sauerbrei W, Multivariate Model Building. A Pragmatic Approach to Regression Analysis Based on Fractional Polynomials for Modeling Continuous Variables 2008 Chichester, United Kingdom Wiley
40. Royston P, Sauerbrei W, A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med 2004 23 2509 2525. doi: 10.1002/sim.1815
41. Grønnesby JK, Borgan O, A method for checking regression models in survival analysis based on the risk score. Lifetime Data Anal 1996 2 315 328
42. Royston P, Sauerbrei W, A new measure of prognostic separation in survival data. Stat Med 2004 23 723 748. doi: 10.1002/sim.1621
43. Royston P, Sauerbrei W, Bootstrap assessment of the stability of multivariable models. Stata J 2009 9 547 570
44. Vickers AJ, Decision analysis for the evaluation of diagnostic tests, prediction models and molecular markers. Am Stat 2008 62 314 320. doi: 10.1198/000313008X370302
45. Nieto FJ, Coresh J, Adjusting survival curves for confounders: a review and a new method. Am J Epidemiol 1996 143 1059 1068
46. Mardon K, Montagne O, Elbaz N, Malek Z, Syrota A, Dubois-Randé JL, Meignan M, Merlet P, Uptake-1 carrier downregulates in parallel with the beta-adrenergic receptor desensitization in rat hearts chronically exposed to high levels of circulating norepinephrine: implications for cardiac neuroimaging in human cardiomyopathies. J Nucl Med 2003 44 1459 1466
47. Grassi G, Bolla G, Seravalle G, Turri C, Lanfranchi A, Mancia G, Comparison between reproducibility and sensitivity of muscle sympathetic nerve traffic and plasma noradrenaline in man. Clin Sci (Lond) 1997 92 285 289
48. Goldstein DS, Bentho O, Park MY, Sharabi Y, Low-frequency power of heart rate variability is not a measure of cardiac sympathetic tone but may be a measure of modulation of cardiac autonomic outflows by baroreflexes. Exp Physiol 2011 96 1255 1261. doi: 10.1113/expphysiol.2010.056259